What Inmedix does

Inmedix is a Seattle-based, privately held medtech company that has built the CloudHRV System, an FDA 510(k)-cleared, cloud-based diagnostic that performs a 5-minute, medical-grade heart rate variability (HRV) analysis to assess both sympathetic and parasympathetic activity of the autonomic nervous system. The company positions its work in the field of 'immuno-autonomics,' focused on the intersection of autonomic nervous system function and autoimmune disease, with stated applications in rheumatoid arthritis, fibromyalgia, multiple sclerosis, and other conditions where autonomic dysregulation affects treatment outcomes. CloudHRV is described as the first FDA-cleared cloud-based HRV diagnostic, marketed to rheumatologists, autonomic specialists, and clinical facilities as an objective, point-of-care, insurance-reimbursable procedure.

The company's revenue model is procedure-based and reimbursed by most insurance plans. Following US FDA clearance in January 2025 and US commercial launch in February 2025, the CloudHRV System is actively deployed in Washington, Oregon, Michigan, and Florida, with stated intent to expand to additional sites. The company has reported more than 1,000 procedures completed in the first five months of operation. Commercialization is supported through direct clinical deployment, medical conference presentations, peer-reviewed publications, and an investor relations program, with named clinical partners including Johns Hopkins Lyme Disease Clinic. Inmedix also operates a wholly-owned UK subsidiary (Inmedix UK Ltd., established 2017) supporting patient advocacy partnerships, including the 'Stress Matters' resource with NRAS.

Inmedix is founder-led (CEO Andrew J. Holman MD) with a small team (1-10 employees) and has been funded primarily through Keiretsu Forum network rounds and a $4M bridge convertible note with angel investors in May 2024. The board and advisory bench includes Leroy Hood MD PhD, Kevin J. Tracey MD, Bernard Tobin (former President of Crescendo Bioscience), and Lee S. Simon MD, providing scientific and regulatory depth disproportionate to company size. The company is recognized as #1 Most Valued Company at the Spring 2025 PNW & Rockies Keiretsu Forum Investor Capital Expo and was named by Fitt/Insider as one of 50 most interesting early-stage startups in health and wellness for 2026.

Name

Inmedix

Legal name

Inmedix, Inc.

Website

https://inmedix.com/

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Inmedix is a Seattle-based medtech company whose FDA-cleared CloudHRV System provides 5-minute, reimbursable heart rate variability diagnostics for healthcare providers treating autoimmune and autonomic-related conditions, with US commercial operations launched in 2025 across four states.

Ownership category

akta.pro rank

Product category

Medical Diagnostics

NAICS

Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Autoimmune, Allergy & Specialized Immunology Diagnostics (HLAHAAAK)

akta.pro secondary industries

Autoimmune & Allergy Diagnostics (HLAAALAK), Autonomic Disorders (Dysautonomia) (HLAKAIAN)

Keywords

• Medical diagnostics
• Heart rate variability
• Autonomic nervous system
• Autoimmune diagnostics
• Clinical HRV analysis

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Clinical Diagnostic Services: Reimbursable diagnostic procedures using the FDA-cleared CloudHRV System, covered by most insurance plans. Revenue generated from clinical procedures performed at healthcare facilities.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Inmedix develops and commercializes the FDA-cleared CloudHRV System, a cloud-based medical-grade heart rate variability (HRV) diagnostic that measures both sympathetic and parasympathetic autonomic nervous system activity in approximately 5 minutes. The company focuses on immuno-autonomics, applying ANS assessment to autoimmune disease management, with clinical diagnostic procedures performed at healthcare facilities and covered by most insurance plans in Washington, Oregon, Michigan, and Florida.

Product overview

Inmedix offers a single unified product—the CloudHRV System—which is an FDA-cleared clinical diagnostic device. This system provides medical-grade, precision heart rate variability analysis to assess autonomic nervous system (ANS) activity. The CloudHRV System measures both sympathetic and parasympathetic components of the ANS in approximately 5 minutes, offering a scalable and reimbursable diagnostic tool for healthcare providers. The company operates primarily in the United States with insurance coverage in Washington, Oregon, Michigan, and Florida, and is expanding to additional sites.

Differentiator

Problem solved

Functional benefit

Brands

• CloudHRV: FDA-cleared medical-grade heart rate variability diagnostic system that measures autonomic nervous system activity.

Products and services

• CloudHRV System FDA-cleared medical-grade heart rate variability (HRV) diagnostic system that measures autonomic nervous system activity in 5 minutes. Assesses both sympathetic (fight-or-flight) and parasympathetic (rest/restorative) neuroregulatory activity for clinical decision support in autoimmune disease management and other conditions. Deployed at healthcare facilities including rheumatology practices, autonomic clinics, and hospital systems; procedures covered by most insurance plans.

Quantifiable outcome

• 1000+ procedures completed in first 5 months
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Six partnerships are on record, tiered core and minor.

• Seattle Children's HospitalcoreStrategic or Co-development PartnerOngoing charitable support partnership with annual fundraising events (golf tournaments) raising funds for kids with arthritis and autoimmune diseases. Multiple years of partnership with record $44,689 raised in September 2025.
• Johns Hopkins Lyme Disease CliniccoreStrategic or Co-development PartnerClinical deployment of CloudHRV System at Johns Hopkins Lyme disease clinic for autonomic nervous system assessment in Lyme disease patients.
• Spaulding Integrative Rehabilitation LaboratoryminorStrategic or Co-development PartnerPilot collaboration announced in September 2022 with Spaulding Integrative Rehabilitation Laboratory (affiliated with Harvard Medical School).
• NRAS (National Rheumatoid Arthritis Society) UKminorGTM or Marketing PartnerUK patient advocacy partnership supporting 'Stress Matters' resources for rheumatoid arthritis patients, with unrestricted educational grant support.
• Random42 LondonminorStrategic or Co-development PartnerCollaboration with Random42 (London) to produce educational animation on immuno-autonomics science.
• Fitt/InsiderminorGTM or Marketing PartnerFeatured in Fitt/Insider 2026 Scouting Report as one of 50 most interesting early-stage health and wellness startups.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Firstbeat: Firstbeat provides HRV analytics for clinical, wellness, and sports performance applications. It is a direct peer as both companies deliver HRV-based autonomic assessment tools used by healthcare and performance professionals, though Firstbeat leans more toward consumer/wellness while Inmedix focuses on FDA-cleared clinical diagnostics.
• Kubios: Kubios offers HRV analysis software used in clinical research, healthcare, and sports science. It is comparable to Inmedix as both companies provide analytical tools for measuring autonomic nervous system function through heart rate variability, with overlapping customer bases in cardiology and autonomic research.
• AliveCor: AliveCor produces FDA-cleared, cloud-connected cardiac diagnostic devices (KardiaMobile) for clinical and consumer use. It is a strong comparable as a company that built a scalable, FDA-cleared, insurance-reimbursable clinical diagnostic ecosystem serving clinicians and patients — a model Inmedix is pursuing in HRV/autonomic assessment.
• Elite HRV: Elite HRV provides HRV analysis applications and educational content for athletes, coaches, and health practitioners. Comparable as a direct HRV analytics peer, though Elite HRV is more consumer/sports focused while Inmedix targets FDA-cleared clinical applications.

Broad incumbents

• Exagen: Exagen develops and commercializes autoimmune diagnostics (Avise CTD, Avise SLE, Avise Vasculitis). It is comparable as a specialty diagnostics company focused on autoimmune disease management, addressing similar rheumatology clinicians and patients — though Exagen's modality is blood-based biomarkers rather than HRV/ANS assessment.
• Myriad Genetics (Crescendo Bioscience): Myriad Genetics acquired Crescendo Bioscience, which commercialized the Vectra DA test for rheumatoid arthritis disease activity. Comparable as a major autoimmune diagnostics incumbent with deep rheumatology KOL relationships and an established commercial channel that overlaps with Inmedix's target specialty audience.
• iRhythm Technologies: iRhythm Technologies is a digital cardiac monitoring company (Zio service) that has scaled an FDA-cleared, cloud-based diagnostic platform with reimbursement and clinician workflow integration. It is a relevant peer for Inmedix as a model of how cloud-first cardiac/autonomic diagnostics can scale commercially in U.S. healthcare.
• Philips (BioTelemetry / Patient Monitoring): Philips, through BioTelemetry and its broader patient monitoring portfolio, provides large-scale cardiac and remote patient monitoring solutions. Comparable as an established incumbent in cardiac/autonomic monitoring that Inmedix's specialized CloudHRV System would either compete against or partner with in clinical workflows.

Emerging players

• Oura: Oura produces a consumer smart ring with HRV tracking among other biometrics. While not a clinical diagnostic, Oura represents the broader trend of consumer-grade HRV measurement that Inmedix must differentiate against for clinical credibility and reimbursement justification.
• Whoop: Whoop produces a wearable fitness/HRV band focused on recovery, strain, and sleep. Comparable to Inmedix in measuring HRV and autonomic function but at consumer-grade accuracy — representing both market validation of HRV awareness and a competitive threat at the lower end.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/AndrewJHolman

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds8 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inmedix